SESSION TITLE: Tobacco Cessation and Prevention Posters
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM
PURPOSE: Introduction: Tobacco is the leading cause of preventable disease and death in the world. Therefore it is essential for smokers to quit smoking. Purpose: Present some of the results obtained in a Tobacco Cessation Unit (TCU) in 2010, with special interest in the treatment success.
METHODS: Retrospective descriptive analysis of the results obtained from patients who were attended to in a TCU from January 1st to December 31 in 2010 and the subsequent follow-up to complete a year
RESULTS: 314 of 462 patients (50,6% males), mean age 46,3 years old and 25,5 mean cigarettes/day. Severe comorbidity: respiratory (30,9%), CVRF (59,8%) and psychiatric (44,6%). Different treatments used: 31,8% Nicotine Replacement Therapy (NRT), 9,6% bupropion (BUP), 27,4% varenicline (VRN), 5,4% many of them simultaneously and 25,8% none of them. Continuous abstinence rates at 3, 6, 9 and 12 months follow up for males were 50%, 30%, 27,1% and 25,7% respectively; continuous abstinence rates at 3, 6, 9 and 12 months follow up for females were 55,7%, 46,6%, 44,3% and 39,8%, respectively, and continuous abstinence rates at 3, 6, 9 and 12 months follow up for overall sample were 53,2%, 39,2%, 36,7% and 33,5%, respectively. No s.s. between gender and treatment success, although those patients who completed treatment had s.s. more success (44 of 53 patients - 89%). Overall of the 314 patients, treatment success (one year without smoking) in 53 (16,9%), 18 men and 35 women; percentage rises to 33,5% if we do not consider those who did not attend the second consultation (156). Failure, considered as never abstinent, in 20 (6,7%), 12 males and 8 females. Those who were treated pharmaceutically, greater success for varenicline (17, 30,9%) than NRT (10, 18,9%), bupropion (12, 22,6%) or none (10, 18,9%), s.s. (p=0,022).
CONCLUSIONS: 1. 65,81% did not start treatment (32,04% and 33,77%, first and second appointment respectively). 2. Severe comorbidity, especially CVRF, pshychiatric and respiratory. 3. Continuous abstinence rates were higher for females than males and overall treatment success was 33,5%. 4. Greater success for varenicline than NRT or bupropion-treated
CLINICAL IMPLICATIONS: When patients go to our TCU, they often have severe comorbidity. Smoking cessation treatment is effective but it requires patients' commitment. There is an overall treatment success of 33,5% excluding those who did not attend the second consultation. In our sample, patients treated with varenicline showed a higher success rate than those treated with bupropion or NRT
DISCLOSURE: The following authors have nothing to disclose: Francisco Javier Callejas Gonzalez, Javier Cruz Ruiz, Sergio Garcia Castillo, Ana Isabel Tornero Molina, Marta Genoves Crespo, Abel Jesus Martinez Garcia, Juan Pastrana Calderon, Angel Molina Cano, Claudia Rossana Rodriguez Ortega
No Product/Research Disclosure Information